These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25768248)

  • 1. HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee JH; Lee WK
    Retina; 2015 Aug; 35(8):1561-8. PubMed ID: 25768248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
    Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
    Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM; Koh HJ; Lee CS; Lee SC
    Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.
    Sakai T; Ohkuma Y; Kohno H; Hayashi T; Watanabe A; Tsuneoka H
    Br J Ophthalmol; 2014 Dec; 98(12):1642-8. PubMed ID: 25053762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Sagong M; Lim S; Chang W
    Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
    Kim SJ; Yu HG
    Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
    Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
    Ngo WK; Chee WK; Tan CS; Lim TH
    BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population.
    Sen P; Bhende M; Sachidanandam R; Bansal N; Sharma T
    Indian J Ophthalmol; 2016 Dec; 64(12):908-913. PubMed ID: 28112132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
    Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
    Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
    Lee JH; Lee WK
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
    Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
    Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow-up.
    Desco MC; Mataix J; Garcia-Pous M; Palacios-Pozo E; Navea A
    Retina; 2011 Mar; 31(3):475-81. PubMed ID: 20966825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.